Skip to content
lifestyle.celebhomes.net
Home
Sample Page
Author:
Kyverna Therapeutics, Inc.
Kyverna Presents Longer-Term Phase 2 Data for Miv-cel in Generalized Myasthenia Gravis at AAN, Demonstrating Deep, Durable Responses through 52 Weeks
April 20, 2026
Kyverna Therapeutics to Host Conference Call on New Data Across Neuroimmunology Franchise at AAN 2026
April 9, 2026
Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer
February 3, 2026
←
Previous Page
1
2